Last reviewed 2026-04-20 · How we verify

Exelon (rivastigmine)

At a glance

Approved indications

• Alzheimer's disease
• Dementia associated with Parkinson's Disease

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Anorexia
• Headache
• Dizziness
• Fatigue
• Asthenia
• Malaise
• Somnolence
• Increased Sweating
• Tremor

Key clinical trials

• Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease (Phase 4)
• A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26) (Phase 4)
• Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial. (Phase 4)
• Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial (Phase 4)
• Randomized, 2-Way Crossover, Bioequivalence Study of Rivastigmine 1.5 mg Capsules and Exelon Administered as 1 x 1.5 mg Capsule in Healthy Subjects Under Fed Conditions (Phase 1)
• A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/D (Phase 4)
• A Double-Blind, Placebo-controlled Crossover Study to Assess the Pharmacokinetic Profile and the Physiological and Behavioral Effects of Repeat Rivastigmine (Exelon®) Administration in Young Healthy M (NA)
• Improved Language Acquisition Through Neuromodulation, Project Stage Ia (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.